Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com/ and get exclusive access to our numerous stock reports.
Amarin Corporation plc (NASDAQ: AMRN) shares dropped 61.12 percent to close at $2.01 a share Thursday. The stock traded between $1.85 and $2.13 on volume 105.69 million shares traded. The company announced that the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee have voted against the approval of Vascepa.
Get more information on Amarin free access to the in-depth equity report at:
www.FiveStarEquities.com/AMRN
Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) shares surged 11.39 percent to close at $4.50 a share Thursday. The stock traded between $4.28 and $4.53 on volume of 19.51 million shares traded. JPMorgan appears to still be bullish on the company despite recently disclosed side effects of Iclusig. "Our initial view is that the physician community may be far less spooked by the safety update than the investor community," wrote JPMorgan analyst Cory Kasimov.
Get more information on Ariad Pharmaceuticals and free access to the in-depth equity report at:
www.FiveStarEquities.com/ARIA
Aastrom Biosciences Inc. (NASDAQ: ASTM) shares gained 16.84 percent to close at $4.37 a share Thursday. The stock traded between $3.64 and $4.87 on volume of 663,022 shares traded. On Wednesday, the company reported that it’s previously announced one-for-twenty reverse stock split is now effective.
Get more information on Aastrom Biosciences and free access to the in-depth equity report at:
www.FiveStarEquities.com/ASTM
ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) shares jumped 16.43 percent to close at $5.18 a share Thursday. The stock traded between $4.43 and $5.24 on volume of 2.37 million shares traded. The company and Intrexon Corporation announced presentations at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Get more information on ZIOPHARM Oncology and free access to the in-depth equity report at:
www.FiveStarEquities.com/ZIOP
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Five Star Equities
[email protected]